Pentagon Protests Russian Jet Buzzing Antimissile Ship in Black Sea

Global Security Newswire Staff
Global Security Newswire Staff
April 15, 2014, 8:10 a.m.

The Pentagon on Monday cri­ti­cized a Rus­si­an jet’s re­peated buzz­ing of a U.S. an­ti­mis­sile ship sail­ing in in­ter­na­tion­al wa­ters in the Black Sea.

The ac­tion happened on Sunday and in­volved a nuc­le­ar-cap­able — but un­armed — Su-24 fight­er air­craft that made a total of 12 fly­ing passes close to the Ae­gis-equipped USS Don­ald Cook while it con­duc­ted patrol op­er­a­tions in the west­ern Black Sea, the De­fense De­part­ment told re­port­ers.

“The air­craft did not re­spond to mul­tiple quer­ies and warn­ings from Don­ald Cook, and the event ended without in­cid­ent after ap­prox­im­ately 90 minutes,” de­part­ment spokes­man Army Col. Steve War­ren was quoted as say­ing in a Pentagon press story. “This pro­voc­at­ive and un­pro­fes­sion­al Rus­si­an ac­tion is in­con­sist­ent with in­ter­na­tion­al pro­to­cols and pre­vi­ous agree­ments on the pro­fes­sion­al in­ter­ac­tion between our mil­it­ar­ies.”

A second Su-24 ac­com­pan­ied the first Rus­si­an fight­er jet but did not make any passes, War­ren said.

The U.S. mis­sile des­troy­er was re­deployed to the Black Sea in re­cent days in ac­cord­ance with the Pentagon’s ef­forts to as­sure NATO mem­bers and oth­er coun­tries of a U.S. com­mit­ment to their se­cur­ity. The ship’s de­ploy­ment comes amid con­tinu­ing ten­sions with Rus­sia over Mo­scow’s an­nex­a­tion of Ukraine’s Crimean Pen­in­sula and sus­pec­ted in­volve­ment in in­sur­gent ac­tions in the east­ern part of the coun­try.

The USS Don­ald Cook is home-por­ted in Rota, Spain, and is the first of four Ae­gis ships slated for de­ploy­ment in the Medi­ter­ranean as part of the U.S. con­tri­bu­tion to NATO mis­sile de­fense.

“The Don­ald Cook is more than cap­able of de­fend­ing it­self against two Su-24s,” War­ren said.

The Rus­si­an de­fense min­istry last week spoke out against the de­ploy­ment of the war­ship to the Black Sea, say­ing it demon­strated that U.S. an­ti­mis­sile sys­tems in Europe are aimed at un­der­min­ing Rus­sia’s nuc­le­ar de­terrent.

War­ren sug­ges­ted the Su-24 pi­lots were act­ing with some form of ap­prov­al from the Rus­si­an mil­it­ary. “I would have dif­fi­culty be­liev­ing that two Rus­si­an pi­lots, on their own, would choose to take such an ac­tion,” the spokes­man said.

What We're Following See More »
Grassley Open to Lame Duck Hearings on Garland
14 hours ago

Senate Judiciary Committee Chairman Chuck Grassley (R-IA) said Monday he'd now be willing to hold a hearing on Supreme Court nominee Merrick Garland in a lame-duck session of Congress. While he said he wouldn't push for it, he said if "Hillary Clinton wins the White House, and a majority of senators convinced him to do so," he would soften his previous opposition.

Monmouth Has Clinton Up Seven
18 hours ago

In a new Monmouth University poll, 46% of likely voters support Clinton and 39% back Trump, with 7% supporting Libertarian Gary Johnson, and 2% backing Jill Stein of the Green Party. That's down from a poll taken right after the Democratic convention, in which Clinton led by 13 points.

Clinton Advisers Talking to Psychologists, Trump Ghostwriter
18 hours ago

“Hillary Clinton’s advisers are talking to Donald J. Trump’s ghostwriter of The Art of the Deal, seeking insights about Mr. Trump’s deepest insecurities as they devise strategies to needle and undermine him in four weeks at the first presidential debate, the most anticipated in a generation. ... Her team is also getting advice from psychology experts to help create a personality profile of Mr. Trump to gauge how he may respond to attacks and deal with a woman as his sole adversary on the debate stage.”

House Committee Investigating Mylan
21 hours ago

The House Committee on Oversight and Government Reform has requested documents from the CEO of Mylan, "the pharmaceutical company under fire after raising the price of EpiPens more than 400 percent since 2007." Meanwhile, top members of the Energy and Commerce Committee are pressing the FDA on the lack of generic competition for EpiPens.